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 Abstract 
  Background:   Rituximab, an anti-CD20 antibody, effectively depletes B lymphocytes. It is not 
clear whether the use of conventional doses of mycophenolate mofetil (MMF), methylpredniso-
lone and tacrolimus as maintenance immunosuppression in rituximab-treated kidney trans-
plantation is associated with increased risk.  Methods:  We retrospectively evaluated 67 patients 
who underwent HLA-sensitized or ABO-incompatible living donor kidney transplantation after 
one dose of rituximab (200 or 500 mg) (group 1). Eighty-seven kidney transplant recipients who 
did not require rituximab served as a control (group 2).  Results:  Cytomegalovirus infection (16.4 
vs. 5.7%, p = 0.031) and pneumonia (9.0 vs. 1.1%, p = 0.043) occurred more often in group 1, and 
2 patients of group 1 died of infection. The doses of methylprednisolone and tacrolimus levels 
of the two groups were not different. MMF dose was reduced when serious infection occurred. 
The doses of MMF (in grams/day) at the following times postoperatively were lower in group 1 
than in group 2: 1 month: 1.26   8   0.42 vs. 1.40   8   0.39, p = 0.033; 3 months: 1.14   8   0.51 vs. 1.36 
  8   0.39, p = 0.011; 6 months: 1.07   8   0.50 vs. 1.30   8   0.42, p = 0.012; 1 year: 0.88   8   0.52 vs. 1.19 
  8   0.44, p = 0.009; 2 years: 0.69   8   0.55 vs. 1.25   8   0.49, p = 0.059, but the reduction of MMF 
doses did not increase the incidence of acute rejection in group 1 (4.5% in group 1 vs. 9.2% in 
group 2, p = 0.351). If patients who died with functioning graft were excluded, graft survival was 
98.5% in group 1 and 100% in group 2.   Conclusions:   Serious infectious complications were in-
creased in rituximab-treated kidney transplant recipients and it might be adequate to reduce 
the MMF dose from the early postoperative period.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
 ABO-incompatible kidney transplantation (ABO-IKT) was started to increase the donor 
pool. In the 1980s, Alexandre et al.   [1]   performed ABO-IKT using plasmapheresis for re-
moval of isohemagglutinins prior to transplantation, and hyperacute rejection was prevent-
ed. Since 1989, more than 1,000 ABO-IKT have been performed in Japan   [2]  . In the 2000s, 
rituximab, a chimeric monoclonal antibody against the protein CD20 which is primarily 
found on the surface of B lymphocytes, was introduced for the management of ABO-IKT  [3, 
4]  . This protocol has become standard in multiple centers after Tydén et al.   [5]   first intro-
duced antigen-specific immunoabsorption combined with anti-CD20 antibody and Son-
nenday et al.   [6]   reported successful ABO-IKT using plasmapheresis, cytomegalovirus 
(CMV) hyperimmune globulin, and anti-CD20 antibody without splenectomy. Thereafter, 
the number of ABO-IKT with rituximab expanded, and long-term outcomes have been re-
ported to be good   [7, 8]  . Transplantations in patients with HLA sensitization have been per-
formed relatively recently. In a recent report of 211 HLA-sensitized living donor kidney 
transplantations (KT), transplantation after desensitization provided a significant survival 
benefit compared with waiting for a compatible organ   [9]  .
    Potential complications from infection after splenectomy could be reduced if this is re-
placed by rituximab in ABO-IKT. However, infection is still a major cause of morbidity and 
mortality of renal transplant recipients. In a study of 1,218 renal transplant recipients, infec-
tion (29%) was the second cause of death just after cardiovascular diseases (38%) in these 
renal transplant recipients   [10]  . Recently, efforts to decrease the infectious complications by 
reducing immunosuppressant are ongoing   [11–14]  . However, it is not known whether stan-
dard doses of maintenance immunosuppressants are adequate in these patients who were 
preconditioned with rituximab.
    In 2009, our center adopted a desensitization protocol for ABO-IKT or HLA-sensitized 
KT, based on plasmapheresis, rituximab and standard immunosuppressive therapy. In this 
study, we retrospectively evaluated the risk of infectious complications in the incompatible 
KT preconditioned with rituximab, and assessed whether the standard maintenance immu-
nosuppression could be reduced without increasing the risk of rejection.
  Patients  and  Methods 
 Patients 
  Between January 2009 and May 2011, 80 patients with end-stage renal disease (ESRD) 
underwent ABO-incompatible or HLA-sensitized living donor KT after preconditioning 
with rituximab, but without splenectomy, at Asan Medical Center in Seoul, Korea. The pa-
tients received tacrolimus, mycophenolate mofetil (MMF), and corticosteroids as mainte-
nance immunosuppressants. Of the 80 patients, 13 patients used other immunosuppressants 
because of side effects or pregnancy. These patients were excluded and the remaining 67 pa-
tients were included in the analysis (group 1). As a control group, 87 living donor kidney 
transplant recipients who underwent compatible KT during the same period in our institu-
tion and received tacrolimus, MMF, and corticosteroids as maintenance immunosuppres-
sants, but not rituximab (group 2) were compared with group 1. This study was approved by 
our local institutional review board (2011-0426).
  Immunosuppression  Protocol 
 The immunosuppression protocol of rituximab-treated renal transplantation is summa-
rized in   figure 1  . Immunosuppressants consisting of tacrolimus, MMF, and methylprednis-68
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olone (mPD) were started 7–10 days before the operation. 1–6 sessions of plasmapheresis 
were performed 3–14 days prior to the operation until anti-A/B antibody titers decreased to 
a level below 1:     4 or T flow cytometry was negative. Plasmapheresis removed immunoglobu-
lin using post-centrifugal plasma filtration by blood cell separator (Cobe Spectra, Caridian 
BCT, USA) and filter (Evaflux 2A, Kawasumi Laboratories, Japan). Rituximab was adminis-
tered 7–10 days before the operation. We used a single dose of 500 mg/body until November 
2009 and reduced the dose to 200 mg/body since then. However, 500 mg/body rituximab 
was administered in patients who were positive on crossmatching with flow cytometry . 
Thus, rituximab was administered as 200 mg in 33 patients and 500 mg in 47 patients. All 
the patients received an induction therapy with anti-CD25 monoclonal antibody (basilix-
imab) on the day of operation and postoperative day 4. Intravenous immunoglobulin (IVIG) 
was not administered.
    In the control patients, anti-CD25 monoclonal antibody was administered on the day of 
operation and postoperative day 4, which is the same as in rituximab-treated patients. Tacro-
limus, MMF and mPD were started 2–3 days before the operation. IVIG was not administered.
    Detection of Anti-A/B Antibody Titers 
  Evaluation of ABO isoagglutinin titers using tube test was applied to measure anti-A/B 
antibody titers. Anti-A/B isoagglutinin titers were determined by incubating 0.1 ml of type 
A and B RBC suspensions in 0.1 ml of saline containing 2-fold serial dilutions of patient’s 
serum at room temperature. The agglutinating activity of IgM isoagglutinin was confirmed 
  Fig. 1.   Immunosuppressive pro-
tocol. Rituximab was adminis-
tered and immunosuppressants 
(tacrolimus, MMF and mPD) 
were started 7–10 days before the 
operation. 1–6 sessions of plas-
mapheresis were performed pri-
or to the operation, and basilix-
imab (anti-CD25 monoclonal 
antibody) was administered on 
the day of operation and postop-
eratively on day 4. 
  Fig. 2.   Mortality. Three patients 
(4.5%) died in group 1 whereas 
no mortality case was present in 
group 2 (p = 0.053). 69
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by treating the patient’s serum with 0.01 mmol/l dithiothreitol, which abolished its aggluti-
nating property.
    HLA Typing and Crossmatch 
  HLA was typed with absolute HLA PCR/SSP kit (BioSewoom Inc., Korea) using se-
quence-specific primer. To exclude false negatives, control primer was used as positive con-
trol of PCR. HLA crossmatch was performed with T flow cytometry. Mean fluorescence 
intensity (MFI)   6  2.0 was read as positive.
  Diagnosis  of  Rejection 
  Surveillance biopsies were not performed routinely. When clinically indicated by rising 
serum creatinine or decreasing urine output, renal biopsies were performed to confirm re-
jection. C4d staining was performed with standard immunofluorescence techniques in all 
specimens. Acute cellular rejection and acute antibody-mediated rejection were diagnosed 
on the basis of the Banff criteria.
    Definition and Prophylaxis of Infection 
 CMV infection was defined as positivity for CMV antigenemia assay   6 50 cells/200,000 
WBC and treated with ganciclovir. CMV antigenemia assay was performed with Light Di-
agnostics CMV pp65 Antigenemia kit (Chemicon International, Temecula, Calif., USA). BK 
virus infection was diagnosed when plasma DNA load was greater than 10,000 copies/ml, 
regardless of nephropathy. BK virus PCR was performed with Real-Q BKV quantitation kit 
(Biosewoom, Seoul, Korea). For PCP prophylaxis, oral trimethoprim/sulfamethoxazole 
(80/400 mg) was administered daily for 6 months postoperatively. CMV prophylaxis was not 
given routinely. We checked CMV antigenemia assay periodically, and treated CMV infec-
tion when it occurred.
  Statistical  Analysis 
  All statistical analyses were performed with SPSS 18. Data are expressed as means and 
standard deviation. Categorical variables were compared using the     2   test or Fisher’s exact 
test, and continuous variables were compared using the t test (or Mann-Whitney U test) and 
ANOVA (or Kruskal-Wallis test). Mortality rates were estimated by the Kaplan-Meier meth-
od, tested by log-rank test. A two-tailed p value  ! 0.05 was considered statistically significant.
  R e s u l t s  
  Clinical Characteristics of the Patients 
  The patients’ baseline characteristics are shown in   table 1  . There were more men than 
women in both groups. Patients’ mean ages in group 1 and group 2 were 44.88   8   11.65 and 
42.72  8  10.39 years, respectively (p = 0.228). Etiologies of ESRD and past medical history in 
the two groups were not significantly different.
    Doses of Maintenance Immunosuppressants 
  Drug levels and doses of the immunosuppressants are shown in   table 2  . The drug levels 
of tacrolimus and the doses of mPD after 6 months, 1 and 2 years after transplantation 
showed no difference between the two groups. MMF dose was reduced when CMV, BK virus 
infection and severe infection such as sepsis occurred. This decision was made by clinician’s 
judgment. The doses of MMF (in grams/day) at 1 month, 3 months, 6 months, 1 year and 2 
years postoperatively were significantly lower in group 1 than in group 2.70
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  Incidence  of  Infection 
  Infections occurred in 52.2% (35 patients) of group 1 and 40.2% (35 patients) of group 2 
(p = 0.138). However, CMV infection (16.4% in group 1 and 5.7% in group 2, p = 0.031) and 
pneumonia (9.0% in group 1 and 1.1% in group 2, p = 0.043) occurred more often in group 
1. The incidences of BK virus infection, urinary tract infection, sepsis and other infections 
including candida, herpes simplex virus and intra-abominal infection showed no significant 
difference between the two groups (  table 3  ).
  Graft  Rejection 
  There was no hyperacute rejection or antibody-mediated rejection in either group 1 or 
group 2. Acute cellular rejection occurred in 3 patients (4.5%) in group 1 and 8 patients (9.2%) 
in group 2 (p = 0.351). Chronic rejection occurred only in 1 patient of group 2. There was no 
Table 1. B  aseline clinical characteristics
Group 1 (n = 67) Group 2 (n = 87) p value
Sex (male/female) 42/25 46/41 0.252
Age, years 44.88811.65 42.72810.39 0.228
Dialysis (hemodialysis/peritoneal) 57/6 54/13 0.139
Dialysis duration, month 32.11833.47 31.04839.09 0.868
Etiology of ESRD 0.541
Diabetes mellitus 14 21
Hypertension 12 23
Glomerulonephritis 16 15
Vesicoureteral reflux 4 1
Polycystic kidney disease 5 5
Unknown etiology 11 15
Other causes 5 7
Past medical history
Diabetes mellitus 15 23 0.579
Hypertension 57 73 0.843
Hepatitis 6 2 0.079
Autoimmune disease 0 1 1.000
Malignancy history 3 0 0.080
Mean follow up time, months 12.6387.59 11.1088.16 0.238
Donor to recipient
Compatible 21 87
A ] B1 1 –
B ] A8 –
A/B ] O1 8 –
AB ] A/B/O 9 –
HLA mismatch (0/1/2/3/4/5/6) 4/0/7/20/7/18/11 4/2/12/25/14/19/11 0.790
HLA class I mismatch (0/1/2/3/4) 4/5/27/14/17 5/8/34/23/17 0.877
HLA class II mismatch (0/1/2) 6/33/28 10/49/28 0.442
Donor sex (male/female) 34/33 46/41 0.871
Donor age, years 41.88811.65 43.0089.90 0.521
Donor’s relation with recipient 0.849
Parents 7 8
Siblings 20 36
Children 11 6
Spouse 21 22
Others 8 1571
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significant difference in the incidence of acute cellular rejection and chronic rejection be-
tween the two groups (  table 4  ).
  Serum  Creatinine  Level 
  After renal transplantation, creatinine levels were not significantly different in the two 
groups. Preoperative levels of creatinine (in     mol/l) in group 1 and group 2 were 752.28   8  
257.24 and 770.85   8   316.47, respectively (p = 0.692). Postoperative values of creatinine were 
86.63   8   18.56 vs. 97.24   8   27.4 at 2 years (p = 0.614) (  table 5  ).
  Incidence  of  Malignancy 
  Malignancy occurred in two patients of group 1 and none in group 2 (  table 6  ). One pa-
tient developed skin squamous cell carcinoma on the anterior chest wall 8 months after renal 
Table 2. D  oses of immunosuppressants
Group 1 (n = 67) Group 2 (n = 87) p value
Tacrolimus drug levels, ng/ml
Pre KT (67/87) 9.5684.75 11.1186.58 0.104
After 1 month (65/87) 9.1783.22 7.6582.89 0.003
After 3 months (55/71) 7.6482.54 7.8382.88 0.710
After 6 months (48/56) 7.1182.11 6.8082.15 0.463
After 1 year (39/36) 6.5782.13 5.8482.16 0.142
After 2 years (4/9) 5.4881.81 5.7383.95 0.683
Mycophenolate mofetil doses, g/day
Pre KT (67/87) 1.5180.29 1.5580.17 0.325
After 1 month (65/87) 1.2680.42 1.4080.39 0.033
After 3 months (55/71) 1.1480.51 1.3680.39 0.011
After 6 months (48/56) 1.0780.50 1.3080.42 0.012
After 1 year (39/36) 0.8880.52 1.1980.44 0.009
After 2 years (5/10) 0.6980.55 1.2580.49 0.059
Methylprednisolone doses, mg/day
Pre KT (67/87) 16.8486.01 15.9180.86 0.214
After 1 month (65/87) 11.9782.31 11.5982.70 0.358
After 3 months (55/71) 9.0981.48 8.3182.13 0.022
After 6 months (48/56) 7.3381.39 7.5083.46 0.755
After 1 year (39/36) 5.3381.80 6.39810.00 0.519
After 2 years (4/10) 4.0080.00 3.4081.65 0.496
Table 3. I  ncidence of infection
Group 1 (n = 67) Group 2 (n = 87) p value
Incidence of infection 35 (52.2%) 35 (40.2%) 0.138
Cytomegalovirus 11 (16.4%) 5 (5.7%) 0.031
BK virus 9 (13.4%) 7 (8.0%) 0.277
Urinary tract infection 6 (9.0%) 14 (16.1%) 0.192
Pneumonia 6 (9.0%) 1 (1.1%) 0.043
Sepsis 4 (6.0%) 2 (2.3%) 0.404
Others 22 (32.8%) 16 (18.4%) 0.03972
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transplantation. This was removed by excisional biopsy. The other patient was diagnosed 
with parathyroid cancer at 5 months after transplantation. In this patient, calcium level in-
creased gradually after renal transplantation. After ultrasound and parathyroid scan, para-
thyroid adenoma was suspected. However, parathyroid carcinoma was diagnosed after para-
thyroidectomy.
  M o r t a l i t y  
  Three patients (4.5%) died in group 1, whereas there were no deaths in group 2 (  table 7  ). 
One patient died from septic shock associated with urinary sepsis. Fungal infective endocar-
ditis (Aspergillus) was uncontrollable in another patient in spite of mitral valve replacement 
operation. The third patient was improving from pneumonia, but died from metabolic aci-
dosis of unknown origin. Therefore, 2 of 3 deaths were due to infection. Graft survival was 
98.5% in group 1 and 100% in group 2 (p = 0.435). One patient experienced graft failure. 
However, unexpected vessel kinking after operation was the cause of graft failure. Therefore, 
no graft failure occurred by graft rejection.
Table 4. G  raft rejection
Group 1 (n = 67) Group 2 (n = 87) p value
Hyperacute rejection 0 (0%) 0 (0%) –
Acute cellular rejection 3 (4.5%) 8 (9.2%) 0.351
Antibody-mediated rejection 0 (0%) 0 (0%) –
Chronic rejection 0 (0%) 1 (1.1%) 1.000
Table 5. S  erum creatinine levels (mol/l)
Group 1 (n = 67) Group 2 (n = 87) p value
Pre-transplantation (67/87) 752.288257.24 770.858316.47 0.692
After 1 month (66/87) 106.968118.46 91.05829.17 0.223
After 3 months (55/71) 103.43825.64 99.01826.52 0.326
After 6 months (48/56) 106.96827.4 99.01828.29 0.144
After 1 year (39/36) 102.54828.29 93.7826.52 0.152
After 2 years (4/9) 86.63818.56 97.24827.4 0.614
Group 1 (n = 67) Group 2 (n = 87) p value
Malignancy 2 (3.0%) 0 (0%) 0.188
Table 6. I ncidence of malignancy
Group 1 (n = 67) Group 2 (n = 87) p value
Mortality 3 (4.5%) 0 (0%) 0.053
Graft failure 1 (1.5%) 0 (0%) 0.435
Table 7. M  ortality73
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  Discussion 
 In the incompatible KT, hyperacute rejection occurs due to preformed ABO antibody or 
HLA antibody. Plasmapheresis removes the preformed antibody. Rituximab (an anti-CD20 
antibody), which effectively depletes B lymphocytes, has a role in preventing new antibody 
formation until accommodation occurs. Thus, the present immunosuppressive protocol in 
incompatible KT consists of (1) pre-transplant desensitization with plasmapheresis, ritux-
imab and anti-CD25 monoclonal antibody, and (2) the standard maintenance immunosup-
pression of MMF, tacrolimus and steroid at similar doses used in ABO-compatible KT. Be-
cause the additional use of rituximab may result in more immunosuppression, the initial 
standard doses of maintenance immunosuppressants could result in over-immunosuppres-
sion. However, the optimal doses of maintenance immunosuppressants in these patients are 
not known. The occurrence of serious infections is one of the important problems associated 
with over-immunosuppression. There have been several studies that evaluated the associa-
tion of rituximab use with infectious complications. In a study of highly sensitized renal 
transplant recipients   [15]  , 38 patients were treated with rituximab and 26 patients received 
comparable treatment but without rituximab. Severe infectious episodes were not statisti-
cally different between groups and it was concluded that rituximab therapy was not associ-
ated with an increased risk of severe infection. In contrast, several other studies suggested 
the increased risk of infectious complications. In a study of 77 kidney transplant patients who 
received rituximab therapy for various reasons and 902 control patients who received no 
rituximab   [16]  , the incidence of infection was 45.45 and 53.9%, respectively, and showed no 
difference. However, the mortality related to an infectious disease was significantly higher 
in the rituximab group (9.09 vs. 1.55%). Recently, an increased risk of infectious complica-
tions was also reported in ABO-IKT  [17] . In this study, 21 consecutive recipients who under-
went ABO-IKT were compared with ABO-compatible KT recipients. During the follow-up 
for 15.7   8   8.3 months, the rate of viral infections including CMV, herpes simplex virus, 
varicella zoster virus and polyoma virus was significantly increased in ABO-IKT (50 vs. 21%, 
p = 0.038) despite comparable tacrolimus trough levels and MMF and steroid doses. In the 
present study, the overall incidence of infection in the rituximab-treated group was not dif-
ferent from the control group. However, CMV infection and pneumonia occurred more fre-
quently in the rituximab-treated group. In addition, infection was the cause of death in 2 
patients of total 3 deaths in the rituximab-treated group. These findings suggest the need to 
reduce maintenance immunosuppression in rituximab-treated KT.
    In our study, we performed plasmapheresis for desensitization and did not give the pa-
tients IVIG. Most studies of ABO-IKT gave the patients IVIG. There are a few studies in 
which administration of IVIG was not performed in all patients   [18, 19]  . In these studies, no 
serious infection occurred. Although plasmapheresis does not seem to be associated with 
serious infections, the possible role in the increased risk of infection cannot be excluded.
    The main concern associated with reduction in immunosuppression is the occurrence 
of rejection. There have been trials to reduce the rituximab dose from 500 to 200 mg/body 
to prevent major infectious complications  [13, 20] . Shirakawa et al.  [13]  compared the results 
of a low dose of rituximab (200 mg/body) to a usual dose of rituximab (500 mg/body). The 
group treated with the low dose of rituximab showed excellent comparable results. So far, 
however, there has been no data regarding the reduction of maintenance immunosuppres-
sants in rituximab-treated KT. In this study, we reduced MMF when infection occurred. The 
doses of MMF (in g/day) until 2 years postoperatively were lower in group 1 than in group 
2, while kidney function was not different in the two groups. In addition, the incidence of 
acute cellular rejection and chronic rejection was not higher in the rituximab-treated group 
(group 1) who were maintained on lower doses of MMF. One graft was lost in the rituximab-74
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treated group, but anatomical vessel kinking was the cause of graft failure. Though the op-
timum level of dose reduction was not determined in this study, the findings suggest that the 
dose of MMF could be reduced without increasing the risk of rejection in these patients.
    Our study has several limitations. This study was a retrospective cohort study. Thus, 
MMF dose was reduced in incompatible KT not from the early postoperative period, but only 
after the occurrence of serious infection. Second, the follow-up duration was short because 
our institute started ABO-IKT in 2009. Third, we did not analyze the data at each dose of 
rituximab because of the small sample size. Lastly, the possible role of plasmapheresis in the 
increased risk of infection cannot be excluded.
    In conclusion, serious infectious complication was increased in rituximab-treated KT 
and our study suggests the plausibility of reducing maintenance immunosuppressants in 
these patients. It might be adequate to reduce MMF dose from the early postoperative period. 
Prospective randomized controlled studies are warranted to determine the optimal dose of 
maintenance immunosuppression in these patients.
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